<ul> <li><strong>TUE</strong>: EZ M3 (Oct), US Richmond Fed (Nov).</li> <li><strong>WED:</strong> RBNZ Policy Announcement; German Prelim. CPI (Nov), UK
<p>CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation
Leave a Comment